target directory

glp 1 receptor agonist clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT03684642

Source recordAI-normalized

A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Efpeglenatide, developed by Sanofi, is positioned as a once-weekly GLP-1 receptor agonist for the treatment of Type 2 Diabetes Mellitus (T2DM). The asset aims to demonstrate non-inferiority to Dulaglutide, a well-established competitor in the GLP-1 market. The termination of the trial was due to a sponsor decision rather than safety concerns, which may indicate strategic repositioning or resource allocation towards other assets. The competitive landscape includes other GLP-1 therapies, and successful outcomes could enhance market share in a growing diabetes treatment market, which is projected to expand significantly due to increasing prevalence of diabetes globally.

AI analysis

Indication: Type 2 Diabetes Mellitus

Modality: small molecule

Target: GLP-1 receptor agonist

Sponsor: Sanofi

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jun 18, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor agonist

View original source fields

Condition raw: Type 2 Diabetes Mellitus

Condition normalized: Type 2 Diabetes Mellitus

Modality raw: small molecule

Modality normalized: small molecule

Target raw: GLP-1 receptor agonist

Target normalized: GLP-1 receptor agonist

Open report

NCT07622810

Source recordAI-normalized

BALANCE-OBS: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

Carnot Laboratories is advancing Bofanglutide (GZR18) through a Phase 3 clinical trial (BALANCE-OBS) aimed at evaluating its efficacy and safety compared to Semaglutide in Latin American adults with overweight or obesity. The trial's focus on metabolic parameters, cardiovascular risk factors, and quality of life positions Bofanglutide as a potential competitor in the growing obesity treatment market. Given the increasing prevalence of obesity and related comorbidities, successful outcomes could lead to significant market penetration. However, the competitive landscape includes established products like Semaglutide, which has demonstrated efficacy and safety. Diligence is warranted regarding regulatory pathways and potential market access challenges in the Latin American region.